{
    "nct_id": "NCT03139604",
    "official_title": "GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease",
    "inclusion_criteria": "* Has undergone 1 allo-HSCT from any donor (related or unrelated with any degree of HLA matching) and any donor source (bone marrow, peripheral blood stem cells, or cord blood) for a hematologic malignancy or disorder. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible.\n* Clinically suspected Grade II to IV aGVHD as per MAGIC criteria, occurring after allo-HSCT and any GVHD prophylaxis regimen.\n* Evidence of myeloid engraftment. Use of growth factor supplementation is allowed.\n* Serum creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 40 mL/min measured or calculated by Cockroft Gault equation.\n* Willing to avoid pregnancy or fathering children.\n* Able to give written informed consent and comply with all study visits and procedures.\n* Able to swallow and retain oral medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received more than 1 allo-HSCT.\n* Has received more than 2 days of systemic corticosteroids for aGVHD.\n* Presence of GVHD overlap syndrome.\n* Presence of an active uncontrolled infection.\n* Known human immunodeficiency virus infection.\n* Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation.\n* Participants with evidence of relapsed primary disease, or participants who have been treated for relapse after the allo-HSCT was performed.\n* Any corticosteroid therapy for indications other than GVHD at doses > 1 mg/kg per day methylprednisolone (or prednisone equivalent) within 7 days of randomization.\n* Severe organ dysfunction unrelated to underlying GVHD, including:\n\n  * Cholestatic disorders or unresolved veno-occlusive disease of the liver.\n  * Clinically significant or uncontrolled cardiac disease.\n  * Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.\n* Currently breast feeding.\n* Received JAK inhibitor therapy after allo-HSCT for any indication. Treatment with a JAK inhibitor before allo-HSCT is permitted.\n* Treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) of enrollment.\n* Any medical complications or conditions that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.\n* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.",
    "miscellaneous_criteria": ""
}